CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 97 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02656017
NCT02656017Phase 2Completed
CompareCT.gov

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

Kyongtae Ty Bae, M.D., Ph.D.·interventional·Posted Jan 14, 2016·Updated Aug 9, 2022

In Brief

A Phase 2 clinical trial evaluating Metformin and Placebo for Polycystic Kidney, Autosomal Dominant. Completed, enrolled 97 participants across 2 sites.

Detailed Summary

This study will test to see if metformin is safe and if it is tolerated compared to placebo in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages of chronic kidney disease. We will also measure its effect on progression of kidney disease as reflected in the kidney size and the kidney function, along with its effect on kidney pain and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Kidney, Autosomal Dominant
CountriesUnited States
CollaboratorsTufts Medical Center, University of Maryland, Baltimore, University of Southern California, United States Department of Defense

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 14, 2016
Enrollment StartJun 27, 2016
Primary CompletionDec 7, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.5 years ago

Interventions

Metformindrug

Monitoring of tolerability and symptoms.

Placeboother

Monitoring of tolerability and symptoms.